体内
生物
体外
药品
重新调整用途
药物重新定位
药理学
包虫病
泡状棘球蚴病
生物化学
生物技术
生态学
动物
作者
Julia Fabbri,Patricia Eugenia Pensel,Clara María Albani,Valeria B. Arce,Daniel O. Mártire,María Celina Elissondo
出处
期刊:Parasitology
[Cambridge University Press]
日期:2019-08-09
卷期号:146 (13): 1620-1630
被引量:9
标识
DOI:10.1017/s0031182019001057
摘要
Alveolar echinococcosis is a neglected parasitic zoonosis caused by the metacestode Echinococcus multilocularis, which grows as a malignant tumour-like infection in the liver of humans. Albendazole (ABZ) is the antiparasitic drug of choice for the treatment of the disease. However, its effectiveness is low, due to its poor absorption from the gastro-intestinal tract. It is also parasitostatic and in some cases produces side-effects. Therefore, an alternative to the treatment of this severe human disease is necessary. In this context, the repositioning of drugs combined with nanotechnology to improve the bioavailability of drugs emerges as a useful, fast and inexpensive tool for the treatment of neglected diseases. The in vitro and in vivo efficacy of dichlorophen (DCP), an antiparasitic agent for intestinal parasites, and silica nanoparticles modified with DCP (NP-DCP) was evaluated against E. multilocularis larval stage. Both formulations showed a time and dose-dependent in vitro effect against protoscoleces. The NP-DCP had a greater in vitro efficacy than the drug alone or ABZ. In vivo studies demonstrated that the NP-DCP (4 mg kg-1) had similar efficacy to ABZ (25 mg kg-1) and greater activity than the free DCP. Therefore, the repurposing of DCP combined with silica nanoparticles could be an alternative for the treatment of echinococcosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI